Translation Control Therapeutics
Lighting up a novel target space
mRNA translation

AnimaBiotech

We are a technology company with a platform for the discovery of small molecule mRNA drugs. Our technology platform combines novel biology, high scale automated screening and cloud-based computational biology of mRNA imaging analysis with AI software. We develop our own pipeline and partner with pharma on additional targets.

Pharma Collaborations

Anima Biotech announces a strategic collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

Anima Biotech announces strategic collaboration with Takeda to discover and develop mRNA translation modulators for Neurological diseases

Up to $120 million in upfront and preclinical research milestone payments, up to $1.1 billion in clinical and commercial milestones and tiered royalties on sales of any Takeda products resulting from the collaboration. Takeda has a time limited option to expand the collaboration subject to additional payments to Anima of up to $1.2 billion and tiered royalties.

Anima Biotech achieves first milestone in Takeda collaboration

The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles Anima to an undisclosed milestone payment.

For partnering inquiries, please contact [email protected].

Watch Movie: mRNA translation control

A novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against hard targets and undruggable proteins.

Watch Movie: Identification of active and selective mRNA translation modulators

Our technology platform combines novel biology, high scale automated screening and cloud-based computational biology for mRNA image analysis with AI software.

See the Light of Protein Translation

Translation Control Therapeutics platform

Watch Movie: Translation Control Therapeutics Platform

The signature tRNA pair selected by Cerebio for the protein of interest is labeled with fluorescent colors and transfected into cells. Translationlight then generates millions of images showing the translation of the mRNA of the protein in the presence of hundreds of thousands of tested molecules.

The images are uploaded to the cloud for analysis by Brightny where computational biology algorithms for mRNA imaging analysis with AI software identify compounds that decrease or increase the light emitted from the ribosomes. The active molecules are passed on to Compass, where computational and live biology are run in close loop iterations to systematically elucidate their mechanisms of action in the novel target space of mRNA translation modulators.

The Selectivity of Translation Biology

Cells control protein translation using multiple selective mechanisms, offering novel intervention points. Modulation of translation is therefore possible with highly selective drugs.

Tissue
Tissue specific regulation
Cells
Normal vs. cancer cells
Pathway
Up or down regulated in pathological pathway
mRNA
Sequence and structure

mRNA translation modulators
A novel target space

mRNA
Biology
Ribosome accessory proteins
Epitranscriptomics (mRNA modifying proteins)
Splicing factors
Modifiers of ribosomal proteins (Kinases, methylases etc...)
tRNA abundance and control
RNA binding proteins

Small molecule drugs targeting novel proteins involved in the regulation of mRNA translation

mRNA Translation Modulators Pipeline

The high scale automation and integrated technologies in our platform enabled us to develop a broad pipeline across 18 different discovery programs in various therapeutic areas. With our tremendous expertise in mRNA biology, we were able to advance them at unprecedented speed and success rate.

Anima wholly owned pipeline programs are in Fibrosis (tissue selective Collagen I translation inhibitors across several fibrotic diseases), Oncology (c-Myc and K-Ras translation inhibitors with multiple, tumor specific mechanisms of action), Infectious diseases (RSV viral proteins translation inhibitors) and Neuroscience (Tau - Alzheimer’s disease and pain - Nav1.7 translation inhibitors) with additional programs in Repeat Associated Diseases. In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our large scale collaborations with Lilly and Takeda Pharmaceuticals.

Indication Target
Discovery
Optimization
IND enabling
Anima owned
Fibrosis
Lung Fibrosis 1
Collagen-1 2
3
Liver Fibrosis 4
Oncology
c-Myc tumors c-Myc 5
6
7
mKRAS tumors mKRAS 8
Infectious diseases
Respiratory RSV 9
10
Neuroscience
Alzheimer TAU 11
Repeat diseases Undisclosed 12
Pain Nav 1.7 13
Partnered
Huntington mHTT 14
Undisclosed takeda logo lilly logo 15
Undisclosed 16
Undisclosed 17
Undisclosed 18
Anima owned
Partnered
Area Indication mRNA modulation Target
Discovery
Optimization
IND enabling
Fibrosis Lung Fibrosis 1
Collagen-1 2
3
Liver Fibrosis 4
Oncology c-Myc tumors c-Myc 5
6
7
mKRAS tumors mKRAS 8
Infectious diseases Respiratory RSV 9
10
Neuroscience Alzheimer TAU 11
Repeat diseases Undisclosed 12
Pain Nav 1.7 13
Undisclosed takeda logo lilly logo 14
Huntington mHTT 15
Undisclosed 16
Undisclosed 17
Undisclosed 18

17 Scientific Collaborations

15 Peer Reviewed Publications

Coverage

News & Events

  • Anima Biotech achieves first milestone in Takeda collaboration

    The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles Anima to an undisclosed milestone payment.

  • Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs

    When: May. 18th, 2021 - May. 19th, 2021

    Anima Biotech has been invited to participate in both a presentation and a live panel discussion at the Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs Conference.

    Visit the conference website »

  • Sachs 4th Annual Neuroscience Innovation Forum

    When: Apr. 28th, 2021 - Apr. 30th, 2021

    Anima Biotech has been invited to participate in a live panel discussion at the Sachs 4th Annual Neuroscience Innovation Forum.

    Download Press Release »

    Visit the conference website »